Because CF is a multisystemic disease, prior to the introduction of CF transmembrane conductance regulator (CFTR) modulators, therapy included symptomatic treatment and management of pulmonary exacerbations and other complications by controlling airway infections and inflammation, mobilizing secretions to reduce airway obstruction, and correcting gastrointestinal symptoms and nutritional deficits caused by pancreatic insufficiency [12–15]. Here, CFTR is linked to cystic fibrosis.